The proinflammatory transcription factor nuclear factor-kB (NF-kB) has a central role in host defence against pneumococcal disease. Both rare mutations and common polymorphisms in the NFKBIA gene encoding the NF-kB inhibitor, IkB-a, associate with susceptibility to bacterial disease, but the possible role of polymorphisms within the related IkB-z gene NFKBIZ in the development of invasive pneumococcal disease (IPD) has not been reported previously. To investigate this further, we examined the frequencies of 22 single-nucleotide polymorphisms spanning NFKBIZ in two case-control studies, comprising UK Caucasian (n ¼ 1008) and Kenyan (n ¼ 723) individuals. Nine polymorphisms within a single UK linkage disequilibrium (LD) block and all four polymorphisms within the equivalent, shorter Kenyan LD block displayed either a significant association with IPD or a trend towards association. For each polymorphism, heterozygosity was associated with protection from IPD when compared with the combined homozygous states (for example, for rs600718, Mantel-Haenszel 2 Â 2 w 2 ¼ 7.576, P ¼ 0.006, odds ratio (OR) ¼ 0.67, 95% confidence interval (95% CI) for OR: 0.51-0.88; for rs616597, Mantel-Haenszel 2 Â 2 w 2 ¼ 8.715, P ¼ 0.003, OR ¼ 0.65, 95% CI: 0.49-0.86). We conclude that multiple NFKBIZ polymorphisms associate with susceptibility to IPD in humans. The study of multiple populations may aid in fine mapping of associations within extensive regions of strong LD ('transethnic mapping').
Introduction
Streptococcus pneumoniae is a major global health problem and a leading cause of death in children worldwide. 1 Invasive pneumococcal disease (IPD) occurs when S. pneumoniae invades a normally sterile site, most commonly blood (bacteraemia), and is associated with a mortality rate of at least 20% even in developed countries. [1] [2] [3] Although asymptomatic nasopharyngeal carriage of the pneumococcus is common in the general population, invasive disease develops in only a minority of individuals and the factors that determine invasion remain poorly understood. 4 Increasing evidence from mouse models and rare human primary immunodeficiency states supports a central role of the proinflammatory transcription factor nuclear factor-kB (NF-kB) in host defence against pneumococcal disease.
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Activation of NF-kB occurs after stimulation of various immune receptors, including toll-like receptors, members of the interleukin-1 (IL-1) and tumour necrosis factor receptor superfamilies, as well as the IL-17 receptor. Control of NF-kB is mediated through direct interactions with a family of IkB inhibitors. The beststudied IkB members are the proteins IkB-a, IkB-b and IkB-e, which trap NF-kB in the cytoplasm of unstimulated cells. 11 The most recently described member of the IkB family is the protein IkB-z, encoded by the gene NFKBIZ. IkB-z differs from the major IkBs, namely IkB-a, IkB-b and IkB-e in that it is localized in the nucleus rather than in the cytoplasm. 12, 13 Unlike the cytoplasmic IkBs, very little IkB-z protein is detected in resting macrophages or in lung primary cells; however, IkBz mRNA is rapidly induced after toll-like receptor/IL-1 signalling. 12, [14] [15] [16] Two variants of IkB-z mRNA appear to be generated as a result of alternative splicing: long IkB-z(L) and short IkB-z(S). The short form lacks exon 3 that contains the initiation codon of IkB-z(L), and as a result encodes a shorter protein from a downstream initiation site, lacking the amino-terminal 99 amino acids of IkBz(L).
13,14
The IkBz promoter region contains NF-kB binding sites, and indeed NF-kB has been shown to be essential for the induction of IkBz.
14 IkB-z in turn acts as an inhibitor of NF-kB and is likely to be regulated by NF-kB in a fast negative feedback loop, as has been shown for the inhibitor IkB-a. 16 A further difference between IkB-z and the cytoplasmic IkBs is that, in addition to exerting an inhibitory effect on NF-kB, IkB-z also demonstrates intrinsic transcriptional activity and appears to be essential for the activation of a subset of inflammatory genes, including IL-6. 12, 13, 15, 17 In addition, IkB-z seems to act as a negative regulator of tumour necrosis factor-a signalling in mice, 15, 18 and may therefore have a role in specific signalling in response to subgroups of proinflammatory cytokines. The functional consequences of IkB-z activation remain incompletely understood, and are further complicated by apparent differences in IkB-z signalling between cell lines, mice and humans. 16, 18 Recent work has shown that both rare mutations and common polymorphisms in the NFKBIA gene encoding the NF-kB inhibitor IkB-a are associated with susceptibility to bacterial disease in humans. 5, 6, 19 However, the possible role of polymorphism within the related IkB-z gene NFKBIZ in the development of human disease has not been studied previously. To investigate this further, we studied the frequencies of polymorphisms in the NFKBIZ gene in European and African individuals with IPD and controls.
Subjects and methods

Sample information
The UK Caucasian IPD sample collection has been described previously. 20 Blood samples were collected on diagnosis from all hospitalized patients with microbiologically proven IPD (defined by the isolation of S. pneumoniae from a normally sterile site, most commonly blood) as part of an enhanced active surveillance programme in three hospitals in Oxfordshire, UK (namely John Radcliffe, Horton General and Wycombe General Hospitals). Consecutive cases of IPD were enrolled between June 1995 and May 2001. There were no exclusion criteria for the study. DNA samples were obtained from 275 patients. Clinical details, including age, gender, clinical presentation and the presence of underlying risk factors, were recorded on a standardized proforma. During the study, Oxfordshire was a region of very low HIV (human immunodeficiency virus) prevalence and HIV testing was not conducted routinely. Frequencies of initial clinical presentation were as follows: pneumonia 69%, isolated bacteraemia 15%, meningitis 11% and other presentations 5%. The mean age of the patients was 58 years, ranging from 0 to 94 years; 50% of them were male. Pneumococcal serotypes were identified using polyclonal rabbit antisera (Statens Seruminstitut, Copenhagen, Denmark). The distribution of serotypes was very similar to that of previous UK studies, with serotype 14 being the most common.
The control group comprised a combination of 163 UK healthy adult blood donors and 570 cord blood samples. For the cord samples, blood was collected anonymously from the discarded umbilical cords of healthy neonates born at the John Radcliffe Hospital (Oxford, UK) as described previously. 20 Examination of microsatellite markers excluded contamination with maternal DNA. The study of cord blood samples is intended to reveal background population allele frequencies; recent extensive use of a UK birth cohort control group for association studies of multiple disease phenotypes has confirmed the validity of such an approach. 21 The mean age of the adult blood donors was 38 years, and 50% were male; in addition, 54% of the cord blood donors were male. Individuals of non-European ancestry were excluded from cases and controls. The study was approved by the research ethics committees of the participating hospitals.
The Kenyan bacteraemia case-control collection has also been previously described. 22 Kenyan children (aged o13 years) with bacteraemia were recruited from Kilifi District hospital between 1998 and 2002. The 687 bacteraemic cases comprised patients with isolated Gram-positive and Gram-negative infections, diagnosed using standard blood culture techniques. The most frequent organisms isolated were S. pneumoniae (25%), non-Typhi Salmonella species (16%), Haemophilus influenzae (14%) and Escherichia coli (8%). The 550 community controls were individually matched to a subset of the cases on the basis of time (recruited within 14 days), location of homestead, age and sex. Only children with complete data for HIV, malnutrition and malaria status were included in the analysis. Ethical approval for the study was given by the KEMRI (Kenya Medical Research Institute) National Scientific Steering and Research Committees.
Genotyping techniques DNA extraction from blood was performed using Nucleon II kits (Scotlab Bioscience, Buckingham, UK). Polymorphisms within NFKBIZ and neighbouring chromosomal regions were selected from the dbSNP (http:// www.ncbi.nlm.nih.gov) and ensembl (http://www. ensembl.org) databases. Polymorphisms were chosen on the basis of their likely functionality, as well as to provide an overview of the extent of linkage disequilibrium (LD) across the gene and flanking regions. Genotyping was performed using the Sequenom Mass-Array MALDI-TOF primer extension assay (Sequenom Inc, San Diego, CA, USA). 23 
Statistical analysis
Statistical analysis of genotype associations and logistic regression was performed using the program SPSS v16.0 (SPSS). Analysis of LD was performed using the Haploview v4.1 program. 24 Haplotype blocks were defined as regions demonstrating strong evidence of historical recombination between o5% of single-nucleotide polymorphism (SNP)-pair comparisons. 25 All control genotype distributions were in the Hardy-Weinberg equilibrium.
Results
A total of 22 SNPs were genotyped in the UK Caucasian IPD cases and controls, of which 7 SNPs were nonpolymorphic or very rare (Table 1) . Of the remaining 15 SNPs, 7 appeared to be associated with susceptibility to IPD at the 0.05 significance level ( Table 1 ). The seven associated SNPs span a distance of 20 kb across the gene, from intron 2 (rs685666) to the 3 0 -untranslated region (rs601225). Flanking polymorphisms on either side of NFKBIZ were also genotyped to determine the extent of LD and to exclude the possibility that the associated SNPs were simply markers linked to a true association in a neighbouring gene. The disease-associated SNPs were all found to be located within a single block of strong LD, which involves NFKBIZ and extends in a 3 0 direction (Figure 1a) . No other genes are predicted to lie within this region, and the lack of associated SNPs outside this LD block suggests that the observed association is indeed localized to NFKBIZ.
In an attempt to fine map the pneumococcal disease association within such a high-LD region, NFKBIZ polymorphisms were next genotyped in the Kenyan bacteraemia case and control study ( Table 1) . As expected, the extent of LD appeared to be shorter in this African population, with evidence of previous recombination breaking up the extensive 60-kb LD block which was observed in Europeans (Figure 1b) . A smaller LD block was predicted in the Kenyan population, containing only SNPs rs685666, rs6441627, rs616597 and rs600718 (Figure 1b) . Each of these four linked SNPs displayed either a trend towards susceptibility or a significant association with pneumococcal bacteraemia in the Kenyan study (Table 1) , although no association with overall bacteraemia was observed. Of these SNPs, rs600718 and rs616597 displayed the most statistically significant associations with IPD in the Kenyan and UK Caucasian populations; their genotypic distributions are presented in Table 2 . Inclusion of patient covariates (age, comorbid conditions and gender) within a conditional logistic regression framework showed no effect of these factors on genotype in the UK or Kenyan studies, and additionally no effect of HIV infection and proteinenergy malnutrition in the Kenyan study. Neither of the SNPs was associated with outcome from IPD in these groups (data not shown). allele for each SNP in this population. Comparison of ORs for rs600718 and rs616597 did not demonstrate any evidence of heterogeneity between the UK and Kenyan IPD control groups for either SNP; after combining and stratifying the two study groups, heterozygosity was associated with protection from IPD when compared with the combined homozygous states (for rs600718, Mantel-Haenszel 2 Â 2 w 2 ¼ 7.576, P ¼ 0.006, OR ¼ 0.67, 95% CI for OR: 0.51-0.88; for rs616597, Mantel-Haenszel 2 Â 2 w 2 ¼ 8.715, P ¼ 0.003, OR ¼ 0.65, 95% CI: 0.49-0.86). In the context of the shorter LD observed in the Kenyan population, these results localize the IPD disease association to a limited region within NFKBIZ. No further polymorphisms in the vicinity of rs600718 were listed on databases. In an attempt to identify novel polymorphisms, a 2.2-kb region surrounding SNPs rs600718 and rs616597 was sequenced directly in 96 UK Caucasian individuals. The sequenced region comprised the exon downstream of the two SNPs (exon 3 of IkBz(S)) and the entire intron within which the SNPs were located. Only a single new variant was identified, located 21bp 3 0 of exon 3 of IkB-z(S): one individual was found to be CT heterozygous at this position, the remaining individuals sequenced were TT homozygotes. However, the rarity of this intronic variant suggests that it is unlikely to be of any significance to this study. The sequencing also confirmed the genotyping accuracy of SNPs rs600718 and rs616597 (100% concordance between sequencing and Sequenom genotyping).
Discussion
This study has identified associations between multiple NFKBIZ polymorphisms and susceptibility with IPD. The finding that the same SNP (rs600718) independently associates with susceptibility to IPD in both UK and Kenyan populations suggests that this is likely to be a real effect. Although the LD architecture differs between these European and African populations, it is noteworthy that nine SNPs within a single UK LD block and all four SNPs within the Kenyan LD block displayed either a significant association with IPD or a trend towards association. In this context, we believe that the results are unlikely to represent an artefact from multiple testing or population stratification. The absence of an association between NFKBIZ polymorphisms and susceptibility to bacteraemia overall suggests that the effect is likely to be specific to IPD.
Although the finding of multiple associated SNPs within a large LD block provides reasonably compelling evidence of an association with this genomic region, it also renders localization of the functional variant within this block extremely difficult. 26 A theoretical approach to this problem is through the study of the same disease phenotype in another ethnic group. African populations are 'older' than European populations, and as a result have undergone a greater number of recombination events, leading to less extensive LD. 25, 27 The study of a second population may therefore aid in fine mapping of associations within extensive regions of strong LD ('transethnic mapping'). Furthermore, it has been argued that the demonstration of genetic loci that impact on disease susceptibility across different populations is perhaps of even more value than the identification of population-specific effects. 28 However, genetic studies incorporating more than one ethnic group remain relatively unusual, reflecting the challenge in assembling adequate sample collections from individuals with the same phenotype in different populations.
The differing frequency of the rs600718 and rs616597 mutant alleles between European and African populations is noteworthy: frequencies of B22% in the UK Caucasians and B6% in the Kenyans were observed. The UK genotype distributions suggest that mutant homozygotes are particularly vulnerable to IPD, and in the setting of a developing country with a very high burden of pneumococcal disease mortality, such genotypes are likely to be subjected to significant negative selective pressure. Therefore, the mutant allele frequency noted in NFKBIZ gene and pneumococcal disease SJ Chapman et al the Kenyan population may reflect a balance between a deleterious effect of the mutant homozygous state versus a possible evolutionary benefit from heterozygosity. Heterozygote protection against major infectious disease phenotypes is well-described, [29] [30] [31] [32] and may also result from additional selective pressures acting at this locusinvestigation of NFKBIZ in the setting of other major infectious and inflammatory disease phenotypes may therefore be of interest.
To our knowledge, this is the first reported disease association with NFKBIZ, and the identity of the IPDassociated polymorphism, which exerts a functional effect on NFKBIZ, remains unclear. A study of the Kenyan population suggests that the true functional variant is likely to be either rs600718 itself, or a polymorphism within this LD block tagged by rs600718. The SNP rs600718 is located in the intron between exon 1 of IkB-z(L) and exon3 of IkB-z(S); it does not itself appear to disrupt a splice site and its possible effects on IkB-z gene function are unknown. Stabilization of IkBz mRNA has recently been shown to be required for stimulus-specific IkBz induction, 14 and it is possible that a NFKBIZ polymorphism may exert a functional effect through modulation of the rate of mRNA degradation.
IkB-z is known to be highly expressed in the lungs and on mucosal surfaces, 16, 33 consistent with a role in host defence against the pneumococcus. The mechanism by which IkB-z variation influences the development of IPD is likely to be complex, given the apparent dual actions of IkB-z on NF-kB signalling. The requirement for IkB-z in the expression of a subset of inflammatory genes, in particular that of IL-6, may account for its role in susceptibility to IPD. A further possibility is that IkB-z variation modulates IL-17A signaling in response to pneumococcal infection. IL-17A has been shown to mediate immunity to pneumococcal colonization, perhaps in part reflecting the induction of human b-defensin 2 (hBD-2), which exerts a potent inhibitory effect on pneumococcal growth. [34] [35] [36] Indeed, IkB-z has recently been reported to have a key role in the induction of hBD-2 expression in airway epithelium in response to IL-17A. 36 There is increasing evidence that IL-17A is central to the control of inflammatory airway responses, 37 and the possible role of NFKBIZ polymorphisms in the regulation of pneumococcal clearance after IL-17A-induced hBD-2 expression is worthy of further investigation. IkB-z is itself the subject of considerable interest and ongoing research is likely to clarify its precise signalling roles. This study adds to the increasing evidence that control of NF-kB is central to host defence against pneumococcal disease in humans, and for the first time highlights a role of IkB-z in this process.
